Program
SPG-302
Also written as “SPG302” and “Tazbentetol”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Schizophrenia, led by Spinogenix.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Spinogenix | 63 open or running | phase 3since Jan 6, 2026 | May 22, 2023 | Dec 31, 2027phase 3 · NCT07325591 |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2023First study: phase 1 study in Amyotrophic Lateral SclerosisFirst studyNCT05882695 · 88 enrolled · Australia
- May 13, 20242 phase 2 studiesNCT06427668, NCT06442462
- Feb 12, 2025Phase 2 study in Alzheimer DiseaseNCT06833281 · 12 enrolled · Australia
- Mar 24, 2025Phase 2 study in Amyotrophic Lateral SclerosisNCT06903286 · 16 enrolled · Australia
- Jan 6, 2026Phase 3 study in Amyotrophic Lateral SclerosisPhase 3 reachedNCT07325591 · 430 planned
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07325591
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07325591Amyotrophic Lateral Sclerosis | 3 | Not yet recruiting | Dec 31, 2027 | 430 |
| NCT06903286Amyotrophic Lateral Sclerosis · Australia | 2 | Terminated | Jun 30, 2025 | 16 |
| NCT06833281Alzheimer Disease · Australia | 2 | Terminated | Jul 30, 2025 | 12 |
| NCT06442462Schizophrenia · United States, Australia | 2 | Active, not recruiting | Mar 2026 | 32 |
| NCT06427668Alzheimer Disease · Australia | 2 | Active, not recruiting | Dec 2025 | 24 |
| NCT05882695Amyotrophic Lateral Sclerosis · Australia | 1 | Completed | Jun 27, 2025 | 88 |
How it is read
Names in the registry
- “SPG302”, 5 entries
- “Tazbentetol”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 3 studies
- Alzheimer Disease, 2 studies
- Schizophrenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.